Biohaven announces presentation at the american society for experimental neurotherapeutics (asent) annual meeting

Bhv-7000 differs pharmacologically and structurally from other known kv7 compounds in development bhv-7000 demonstrates potent anti-seizure activity without effects on neurobehavior in preclinical models bhv-7000 cns side effect profile in phase 1 compares favorably to anti-seizure medications currently approved and in clinical development    new haven, conn. , march 14, 2023 /prnewswire/ -- biohaven ltd.
BHVN Ratings Summary
BHVN Quant Ranking